Shoichi Kuyama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shoichi Kuyama has a total of 107 co-authors. Here are the top co-authors by number of shared publications:
- Terufumi Kato
Center for Clinical Research and Trials Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Tokyo Japan
18 shared publications - Go Makimoto
Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan
16 shared publications - Kazumi Nishino
Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan
16 shared publications - Hibiki Udagawa
Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan
15 shared publications - Hiroki Izumi
Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan
15 shared publications - Kadoaki Ohashi
Department of Respiratory Medicine Okayama University Hospital Okayama Japan
15 shared publications
Latest Publications
- Open Access
- 9 September 2026
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (10)
Preventive effect of goshajinkigan on paclitaxel-induced peripheral neuropathy: an open-label, randomized phase II study (OLCSG2101)
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting toxicity of paclitaxel (PTX)-containing regimens, and no preventive strategy has been established. We evaluated goshajinkigan (GJG), a traditional Japanese herbal medicine (Kampo), for preventing CIPN during PTX-containing chemotherapy. Materials and Methods: In this open-label, randomized phase II trial across 7 institutions in Japan, patients with malignant tumors scheduled for ≥4 courses of carboplatin plus PTX (≥150 mg/m²) were randomized 1:1 to GJG or control, with minimization by cancer type and age. The primary endpoint was grade ≥2 CIPN incidence within 4 courses. The protocol-prespecified primary analysis used an unstratified 2-sided log-rank test (α = 0.10); a supportive stratified analysis accounted for the minimization factors. Results: Sixty-five patients were randomized (GJG, 32; control, 33); 52 (80.0%) had lung cancer. Grade ≥2 CIPN occurred in 28.1% (9/32) of the GJG arm vs 51.5% (17/33) of the control arm; the protocol-prespecified unstratified log-rank P value was .013, with a corresponding HR of 0.34 (90% CI, 0.16-0.72). In the stratified analysis accounting for cancer type and age, the estimate remained in favor of GJG but was attenuated and less precise (HR, 0.48; 90% CI, 0.22-1.02; stratified log-rank P = .101). Grade 3-5 adverse-event incidence was similar between arms. Conclusion: GJG was associated with fewer grade ≥2 CIPN events in this predominantly lung-cancer population. Given the open-label design and uncertainty in the stratified analysis, these findings represent a phase II preventive signal warranting confirmation in a double-blind, placebo-controlled phase III trial. Clinical trial registration number: Japan Registry of Clinical Trials (jRCTs061210047).
- 9 September 2026
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (10)
Open AccessPreventive effect of goshajinkigan on paclitaxel-induced peripheral neuropathy: an open-label, randomized phase II study (OLCSG2101)
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting toxicity of paclitaxel (PTX)-containing regimens, and no preventive strategy has been established. We evaluated goshajinkigan (GJG), a traditional Japanese herbal medicine (Kampo), for preventing CIPN during PTX-containing chemotherapy. Materials and Methods: In this open-label, randomized phase II trial across 7 institutions in Japan, patients with malignant tumors scheduled for ≥4 courses of carboplatin plus PTX (≥150 mg/m²) were randomized 1:1 to GJG or control, with minimization by cancer type and age. The primary endpoint was grade ≥2 CIPN incidence within 4 courses. The protocol-prespecified primary analysis used an unstratified 2-sided log-rank test (α = 0.10); a supportive stratified analysis accounted for the minimization factors. Results: Sixty-five patients were randomized (GJG, 32; control, 33); 52 (80.0%) had lung cancer. Grade ≥2 CIPN occurred in 28.1% (9/32) of the GJG arm vs 51.5% (17/33) of the control arm; the protocol-prespecified unstratified log-rank P value was .013, with a corresponding HR of 0.34 (90% CI, 0.16-0.72). In the stratified analysis accounting for cancer type and age, the estimate remained in favor of GJG but was attenuated and less precise (HR, 0.48; 90% CI, 0.22-1.02; stratified log-rank P = .101). Grade 3-5 adverse-event incidence was similar between arms. Conclusion: GJG was associated with fewer grade ≥2 CIPN events in this predominantly lung-cancer population. Given the open-label design and uncertainty in the stratified analysis, these findings represent a phase II preventive signal warranting confirmation in a double-blind, placebo-controlled phase III trial. Clinical trial registration number: Japan Registry of Clinical Trials (jRCTs061210047).
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Patient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non–Small Cell Lung Cancer
Supplementary Table S1. Representativeness of study participants Supplementary Table S2. Averagea change from baseline in prespecified key EORTC QLQ-C30 and QLQ-LC13 scale scores over all timepoints (MMRM). Supplementary Figure S1. Patient-reported outcome assessment schedules in FLAURA2. Supplementary Figure S2. Patient-reported outcome questionnaire compliance rates. Supplementary Figure S3. Proportion of patients with different A, frequency and B, severity scores for the additional prespecified PRO-CTCAE symptoms at different timepoints. Weeks 13 (3.0 months), 37 (8.5 months), and 97 (22.3 months) of the PRO-CTCAE assessments represent the closest available timepoints to the end of the induction, median pemetrexed maintenance and median osimertinib treatment, respectively, for the osimertinib plus chemotherapy arm. Conditional branching logic was employed for PRO-CTCAE symptom terms that have two or more attributes, thereby reducing the sample size from frequency to severity for symptoms. PRO-CTCAE, Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Patient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non–Small Cell Lung Cancer
Supplementary Table S1. Representativeness of study participants Supplementary Table S2. Averagea change from baseline in prespecified key EORTC QLQ-C30 and QLQ-LC13 scale scores over all timepoints (MMRM). Supplementary Figure S1. Patient-reported outcome assessment schedules in FLAURA2. Supplementary Figure S2. Patient-reported outcome questionnaire compliance rates. Supplementary Figure S3. Proportion of patients with different A, frequency and B, severity scores for the additional prespecified PRO-CTCAE symptoms at different timepoints. Weeks 13 (3.0 months), 37 (8.5 months), and 97 (22.3 months) of the PRO-CTCAE assessments represent the closest available timepoints to the end of the induction, median pemetrexed maintenance and median osimertinib treatment, respectively, for the osimertinib plus chemotherapy arm. Conditional branching logic was employed for PRO-CTCAE symptom terms that have two or more attributes, thereby reducing the sample size from frequency to severity for symptoms. PRO-CTCAE, Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Patient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non–Small Cell Lung Cancer
Purpose:In FLAURA2, first-line osimertinib plus platinum–pemetrexed induction, with osimertinib plus pemetrexed maintenance, improved progression-free survival versus osimertinib alone in epidermal growth factor receptor (EGFR)-mutated, advanced non–small cell lung cancer (NSCLC; hazard ratio, 0.62; P < 0.001). Combining osimertinib with chemotherapy increased induction grade ≥3 adverse event rates, which reduced during maintenance. We report FLAURA2 patient-reported outcomes (PRO).Patients and Methods:Health-related quality of life (HRQoL) was measured using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ) Core 30 (baseline, week 4, week 7, week 10, then every 6 weeks until progression) and QLQ Lung Cancer 13 (baseline, weekly until week 10, then every 3 weeks until progression). Score changes (baseline to progression/19 months) were analyzed by mixed models for repeated measures. Within-patient ≥10-point changes from baseline were considered clinically meaningful. Tolerability was assessed by PRO-Common Terminology Criteria for Adverse Events (CTCAE).Results:Patients had intermediate-to-high baseline functioning and global health status (GHS)/QoL (mean scores ≥63), with mild symptomatology (≤35). Most key scales showed nonclinically meaningful improvements; average least-squares mean (LSM) changes [95% confidence interval (CI)] for GHS/QoL and physical function, respectively, were 3.32 (1.67–4.98) and 2.37 (0.70–4.04) with combination therapy and 7.38 (5.70–9.07) and 6.74 (5.04–8.43) with monotherapy. Improvements in cough were clinically meaningful with combination therapy and monotherapy from week 5 (except monotherapy at week 73); average LSM changes (95% CI) were −13.23 (−14.85 to −11.62) and −11.19 (−12.83 to −9.55), respectively. Nonclinically meaningful deteriorations in fatigue and appetite loss were seen with the combination during induction. Both treatments were similarly well tolerated (PRO-CTCAE).Conclusions:In FLAURA2, osimertinib monotherapy and combination with platinum–pemetrexed as first-line treatment for EGFR-mutated advanced NSCLC had nonclinically meaningful impacts on HRQoL in mildly symptomatic patients.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Patient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non–Small Cell Lung Cancer
Purpose:In FLAURA2, first-line osimertinib plus platinum–pemetrexed induction, with osimertinib plus pemetrexed maintenance, improved progression-free survival versus osimertinib alone in epidermal growth factor receptor (EGFR)-mutated, advanced non–small cell lung cancer (NSCLC; hazard ratio, 0.62; P < 0.001). Combining osimertinib with chemotherapy increased induction grade ≥3 adverse event rates, which reduced during maintenance. We report FLAURA2 patient-reported outcomes (PRO).Patients and Methods:Health-related quality of life (HRQoL) was measured using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ) Core 30 (baseline, week 4, week 7, week 10, then every 6 weeks until progression) and QLQ Lung Cancer 13 (baseline, weekly until week 10, then every 3 weeks until progression). Score changes (baseline to progression/19 months) were analyzed by mixed models for repeated measures. Within-patient ≥10-point changes from baseline were considered clinically meaningful. Tolerability was assessed by PRO-Common Terminology Criteria for Adverse Events (CTCAE).Results:Patients had intermediate-to-high baseline functioning and global health status (GHS)/QoL (mean scores ≥63), with mild symptomatology (≤35). Most key scales showed nonclinically meaningful improvements; average least-squares mean (LSM) changes [95% confidence interval (CI)] for GHS/QoL and physical function, respectively, were 3.32 (1.67–4.98) and 2.37 (0.70–4.04) with combination therapy and 7.38 (5.70–9.07) and 6.74 (5.04–8.43) with monotherapy. Improvements in cough were clinically meaningful with combination therapy and monotherapy from week 5 (except monotherapy at week 73); average LSM changes (95% CI) were −13.23 (−14.85 to −11.62) and −11.19 (−12.83 to −9.55), respectively. Nonclinically meaningful deteriorations in fatigue and appetite loss were seen with the combination during induction. Both treatments were similarly well tolerated (PRO-CTCAE).Conclusions:In FLAURA2, osimertinib monotherapy and combination with platinum–pemetrexed as first-line treatment for EGFR-mutated advanced NSCLC had nonclinically meaningful impacts on HRQoL in mildly symptomatic patients.
- Open Access
- 9 March 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (11) , 2144-2156
Patient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non–Small Cell Lung Cancer
Purpose: In FLAURA2, first-line osimertinib plus platinum-pemetrexed induction, with osimertinib plus pemetrexed maintenance improved progression-free survival versus osimertinib alone in EGFR-mutated, advanced non–small cell lung cancer (NSCLC) (HR, 0.62; P < 0.001). Combining osimertinib with chemotherapy increased induction grade ≥3 adverse event rates, which reduced during maintenance. We report FLAURA2 patient-reported outcomes (PROs). Patients and Methods: Health-related quality of life (HRQoL) was measured using EORTC QLQ-C30 (baseline, Week [W] 4, W7, W10, then 6-weekly until progression) and QLQ-LC13 (baseline, weekly until W10, then 3-weekly until progression). Score changes (baseline to progression/19 months) were analyzed by mixed models for repeated measures. Within-patient ≥10-point changes from baseline were considered clinically meaningful. Tolerability was assessed by PRO-CTCAE. Results: Patients had intermediate-to-high baseline functioning and global health status (GHS)/QoL (mean scores ≥63), with mild symptomology (≤35). Most key scales showed non-clinically meaningful improvements; average least-squares mean [LSM] changes (95% CI) for GHS/QoL and physical function, respectively, were 3.32 (1.67–4.98) and 2.37 (0.70–4.04) with combination and 7.38 (5.70–9.07) and 6.74 (5.04–8.43) with monotherapy. Improvements in cough were clinically meaningful with combination and monotherapy from W5 (except monotherapy at W73); average LSM change (95% CI) -13.23 (-14.85 – -11.62) and -11.19 (-12.83 – -9.55), respectively. Non-clinically meaningful deteriorations in fatigue and appetite loss were seen with the combination during induction. Both treatments were similarly well tolerated (PRO-CTCAE). Conclusions: In FLAURA2, osimertinib monotherapy and combination with platinum-pemetrexed as first-line treatment for EGFR-mutated advanced NSCLC had non-clinically meaningful impacts on HRQoL in mildly symptomatic patients.
- 9 March 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (11) , 2144-2156
Open AccessPatient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non–Small Cell Lung Cancer
Purpose: In FLAURA2, first-line osimertinib plus platinum-pemetrexed induction, with osimertinib plus pemetrexed maintenance improved progression-free survival versus osimertinib alone in EGFR-mutated, advanced non–small cell lung cancer (NSCLC) (HR, 0.62; P < 0.001). Combining osimertinib with chemotherapy increased induction grade ≥3 adverse event rates, which reduced during maintenance. We report FLAURA2 patient-reported outcomes (PROs). Patients and Methods: Health-related quality of life (HRQoL) was measured using EORTC QLQ-C30 (baseline, Week [W] 4, W7, W10, then 6-weekly until progression) and QLQ-LC13 (baseline, weekly until W10, then 3-weekly until progression). Score changes (baseline to progression/19 months) were analyzed by mixed models for repeated measures. Within-patient ≥10-point changes from baseline were considered clinically meaningful. Tolerability was assessed by PRO-CTCAE. Results: Patients had intermediate-to-high baseline functioning and global health status (GHS)/QoL (mean scores ≥63), with mild symptomology (≤35). Most key scales showed non-clinically meaningful improvements; average least-squares mean [LSM] changes (95% CI) for GHS/QoL and physical function, respectively, were 3.32 (1.67–4.98) and 2.37 (0.70–4.04) with combination and 7.38 (5.70–9.07) and 6.74 (5.04–8.43) with monotherapy. Improvements in cough were clinically meaningful with combination and monotherapy from W5 (except monotherapy at W73); average LSM change (95% CI) -13.23 (-14.85 – -11.62) and -11.19 (-12.83 – -9.55), respectively. Non-clinically meaningful deteriorations in fatigue and appetite loss were seen with the combination during induction. Both treatments were similarly well tolerated (PRO-CTCAE). Conclusions: In FLAURA2, osimertinib monotherapy and combination with platinum-pemetrexed as first-line treatment for EGFR-mutated advanced NSCLC had non-clinically meaningful impacts on HRQoL in mildly symptomatic patients.
- Open Access
- 6 February 2026
- Published by American Association for Cancer Research (AACR)
Figure 2 from Clinical Characteristics and Spatial Transcriptome Analysis of Non–Small Cell Lung Cancers Exhibiting Early Alectinib Resistance: A Retrospective OLCSG Study
Spatial transcriptome analysis and IHC staining of candidate markers. A, Representative image obtained with the GeoMx DSP system. ROIs were defined within the tumor area. Green: pan-cytokeratin, epithelial cell marker; red: CD68, macrophage marker; yellow: CD45, pan-leukocyte cell marker; and blue: SYTO13, nuclear DNA marker. B, Volcano plot of the RNA expression that is differentially expressed by early resistance and responder groups in the pan-cytokeratin positive areas of ROIs. C–E, Representative images of ANXA1 (C), LCN2 (D), and CLDN4 (E) IHC staining in each patient. Scale bars, 100 μm.
- 6 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Clinical Characteristics and Spatial Transcriptome Analysis of Non–Small Cell Lung Cancers Exhibiting Early Alectinib Resistance: A Retrospective OLCSG Study
Spatial transcriptome analysis and IHC staining of candidate markers. A, Representative image obtained with the GeoMx DSP system. ROIs were defined within the tumor area. Green: pan-cytokeratin, epithelial cell marker; red: CD68, macrophage marker; yellow: CD45, pan-leukocyte cell marker; and blue: SYTO13, nuclear DNA marker. B, Volcano plot of the RNA expression that is differentially expressed by early resistance and responder groups in the pan-cytokeratin positive areas of ROIs. C–E, Representative images of ANXA1 (C), LCN2 (D), and CLDN4 (E) IHC staining in each patient. Scale bars, 100 μm.
- Open Access
- 6 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Clinical Characteristics and Spatial Transcriptome Analysis of Non–Small Cell Lung Cancers Exhibiting Early Alectinib Resistance: A Retrospective OLCSG Study
Receiver operating characteristic (ROC) curves.
- 6 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Clinical Characteristics and Spatial Transcriptome Analysis of Non–Small Cell Lung Cancers Exhibiting Early Alectinib Resistance: A Retrospective OLCSG Study
Receiver operating characteristic (ROC) curves.
- Open Access
- 6 February 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from Clinical Characteristics and Spatial Transcriptome Analysis of Non–Small Cell Lung Cancers Exhibiting Early Alectinib Resistance: A Retrospective OLCSG Study
Effects of IL-6 and ANXA1 on alectinib sensitivity. A, WB analysis of ANXA1, LCN2, and CLDN4 in H3122, ABC-14, ABC-17, ABC-19, and ABC-23 cells. Data are representative of three independent experiments with similar results. B, WB analysis of ANXA1, STAT3, and phospho-STAT3 (pSTAT3) in H3122 cells treated with varying concentrations of IL-6 for 24 hours. Data are representative of three independent experiments with similar results. C, Cell proliferation assays at increasing concentrations with or without IL-6 (20 ng/mL) in H3122 cells treated with alectinib for 72 hours. Data are presented as the mean ± standard error (n = 9 per group). *, P < 0.05, Student t test. D, IC50 values of alectinib in H3122 cells with or without IL-6 treatment (20 ng/mL). Data are presented as the mean ± standard error (n = 9 per group). *, P < 0.05, Student t test. E, WB analysis of ANXA1 expression in ABC-14 cells transfected with negative control siRNA or two different siRNAs targeting ANXA1 (siANXA1 #1, #2). Data are representative of three independent experiments with similar results. F, Cell proliferation assays in ABC-14 cells transfected with negative control siRNA (nega_si) or different siRNAs targeting ANXA1 [siANXA1 #1 (si#1), #2 (si#2)] treated with alectinib (Alec; 0.1 μmol/L) for 72 hours. n = 5 per group. Error bars represent the standard error. *, P < 0.05; ***, P < 0.001, Student t test comparing each siANXA1 group (Alec + si#1 or #2) with the negative control group (Alec + nega_si).
- 6 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Clinical Characteristics and Spatial Transcriptome Analysis of Non–Small Cell Lung Cancers Exhibiting Early Alectinib Resistance: A Retrospective OLCSG Study
Effects of IL-6 and ANXA1 on alectinib sensitivity. A, WB analysis of ANXA1, LCN2, and CLDN4 in H3122, ABC-14, ABC-17, ABC-19, and ABC-23 cells. Data are representative of three independent experiments with similar results. B, WB analysis of ANXA1, STAT3, and phospho-STAT3 (pSTAT3) in H3122 cells treated with varying concentrations of IL-6 for 24 hours. Data are representative of three independent experiments with similar results. C, Cell proliferation assays at increasing concentrations with or without IL-6 (20 ng/mL) in H3122 cells treated with alectinib for 72 hours. Data are presented as the mean ± standard error (n = 9 per group). *, P < 0.05, Student t test. D, IC50 values of alectinib in H3122 cells with or without IL-6 treatment (20 ng/mL). Data are presented as the mean ± standard error (n = 9 per group). *, P < 0.05, Student t test. E, WB analysis of ANXA1 expression in ABC-14 cells transfected with negative control siRNA or two different siRNAs targeting ANXA1 (siANXA1 #1, #2). Data are representative of three independent experiments with similar results. F, Cell proliferation assays in ABC-14 cells transfected with negative control siRNA (nega_si) or different siRNAs targeting ANXA1 [siANXA1 #1 (si#1), #2 (si#2)] treated with alectinib (Alec; 0.1 μmol/L) for 72 hours. n = 5 per group. Error bars represent the standard error. *, P < 0.05; ***, P < 0.001, Student t test comparing each siANXA1 group (Alec + si#1 or #2) with the negative control group (Alec + nega_si).
- Open Access
- 6 February 2026
- Published by American Association for Cancer Research (AACR)
Table 1 from Clinical Characteristics and Spatial Transcriptome Analysis of Non–Small Cell Lung Cancers Exhibiting Early Alectinib Resistance: A Retrospective OLCSG Study
Patient characteristics of early resistance and responder groups.
- 6 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Clinical Characteristics and Spatial Transcriptome Analysis of Non–Small Cell Lung Cancers Exhibiting Early Alectinib Resistance: A Retrospective OLCSG Study
Patient characteristics of early resistance and responder groups.
- Open Access
- 6 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Clinical Characteristics and Spatial Transcriptome Analysis of Non–Small Cell Lung Cancers Exhibiting Early Alectinib Resistance: A Retrospective OLCSG Study
Proposed schematic model of early resistance to alectinib mediated by inflammation.
- 6 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Clinical Characteristics and Spatial Transcriptome Analysis of Non–Small Cell Lung Cancers Exhibiting Early Alectinib Resistance: A Retrospective OLCSG Study
Proposed schematic model of early resistance to alectinib mediated by inflammation.